Orchid Pharma Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a standalone profit of ₹3,675.93 lakh for the quarter and a consolidated profit of ₹2,688.18 lakh. The results were approved by the Board of Directors on November 14, 2026, and include limited review reports from statutory auditors.
Orchid Pharma Announces Q2 FY27 Financial Results
Orchid Pharma Limited, on November 14, 2026, disclosed its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors reviewed and approved these financial statements, which have also received an unmodified conclusion from the statutory auditors.
Standalone Financial Performance
For the standalone operations, Orchid Pharma reported a profit after tax for the quarter ended September 30, 2026, amounting to ₹3,675.93 lakh. The total income from operations for the quarter stood at ₹34,126.66 lakh. The profit for the half-year ended September 30, 2026, was ₹3,675.93 lakh.
Consolidated Financial Performance
On a consolidated basis, the company’s profit for the quarter ended September 30, 2026, was ₹2,688.18 lakh. The total income from operations for the consolidated entity during the same quarter was ₹34,126.66 lakh. The consolidated profit for the half-year ended September 30, 2026, was ₹2,688.18 lakh.
Key Financial Highlights
- Total Income (Standalone): Quarter ended Sep 30, 2026: ₹36,989.74 lakh
- Profit Before Tax (Standalone): Quarter ended Sep 30, 2026: ₹3,675.93 lakh
- Total Income (Consolidated): Quarter ended Sep 30, 2026: ₹35,902.24 lakh
- Profit Before Tax (Consolidated): Quarter ended Sep 30, 2026: ₹2,683.69 lakh
- Total Comprehensive Income (Standalone): Quarter ended Sep 30, 2026: ₹3,645.23 lakh
- Total Comprehensive Income (Consolidated): Quarter ended Sep 30, 2026: ₹2,828.71 lakh
Share Capital and Earnings Per Share
The paid-up equity share capital remains at ₹5,988.52 lakh. For the quarter ended September 30, 2026, the basic earnings per share (EPS) stood at ₹6.14 on a standalone basis and ₹4.77 on a consolidated basis. Diluted EPS was ₹6.14 (standalone) and ₹4.77 (consolidated).
Statement of Assets and Liabilities
As of September 30, 2026, the standalone total assets were ₹2,36,691.01 lakh, with total equity at ₹1,69,302.05 lakh. Consolidated total assets stood at ₹2,65,235.42 lakh, with total equity at ₹1,63,228.16 lakh.
Cash Flow Statement
Cash flow from operating activities (standalone) for the six months ended September 30, 2026, resulted in a net cash inflow of ₹9,071.21 lakh. For the same period, consolidated net cash from operating activities was ₹11,778.46 lakh.
Source: BSE
